FFO
AGIO icon

Fortitude Family Office’s Agios Pharmaceuticals AGIO Stock Holding History

Fortitude Family Office’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74 Hold
2
– – ﹤0.01% 2184
2026
Q1 		$68 Sell
2
-3
-60% -$85 ﹤0.01% 1874
2025
Q4 		$136 Hold
5
– – ﹤0.01% 1881
2025
Q3 		$201 Hold
5
– – ﹤0.01% 1923
2025
Q2 		$166 Buy
+5
New +$152 ﹤0.01% 1974

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Fortitude Family Office's AGIO Position: Q2 2026 in Review

Fortitude Family Office held its Agios Pharmaceuticals (AGIO) position steady in Q2 2026 at 2 shares worth $74. The position accounts for ﹤0.01% of the portfolio, ranked #2184.

Fortitude Family Office first reported a position in AGIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $201 in Q3 2025. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Fortitude Family Office held 2 shares of Agios Pharmaceuticals worth $74 as of Q2 2026.
  • Fortitude Family Office left its Agios Pharmaceuticals share count unchanged in Q2 2026.
  • Agios Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2184 holding.
  • Fortitude Family Office first reported a position in Agios Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Fortitude Family Office's Agios Pharmaceuticals position peaked at $201 in Q3 2025.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.